Under-fire pharma CEO fights back

Elan, the Irish biotech company, has been involved in a high level boardroom row, coming under attack from its own shareholders amid allegations of conflicts of interest with some of the board directors holding shares in companies Elan has done business with. In this week's View from the Top, CEO Kelly Martin fiercely defends the company's position.